Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on October 5, 2011, reporting an event that occurred on September 28, 2011. The filing concerns a material definitive agreement involving the company's wholly-owned subsidiary, Emergent BioDefense Operations Lansing LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The reported transaction is a no-cost modification to an existing contract and does not involve new funding or financial performance metrics.
Material Changes
The primary material change is the extension of the period of performance for a procurement contract with the Centers for Disease Control and Prevention (CDC). The contract, originally dated September 30, 2008, has been extended from September 30, 2011, through December 31, 2011. This modification covers previously funded product and shipping charges and does not include additional doses of BioThrax®.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of new risks or contingencies. The transaction is administrative in nature, extending the timeline for fulfilling existing obligations without altering the financial scope of the agreement.
Key Facts for Investor Verification
- The contract modification with the CDC is at no additional cost to the government.
- The extension applies only to the performance period for previously funded items, not to new product orders.
- The agreement involves the subsidiary Emergent BioDefense Operations Lansing LLC.
- No new revenue or funding is generated by this specific modification.